A specific subtype of non-small-cell lung cancer (NSCLC) characterized with an EML4-ALK fusion gene, which drives constitutive oncogenic activation of anaplastic lymphoma kinase (ALK), shows a good clinical response to ALK inhibitors. We have reported multiple examples implying the biological significance of methylation on non-histone proteins including oncogenic kinases in human carcinogenesis. Through the process to search substrates for various methyltransferases using an in vitro methyltransferase assay, we found that a lysine methyltransferase, SET and MYND domain-containing 2 (SMYD2), could methylate lysine residues 1451, 1455, and 1610 in ALK protein. Knockdown of SMYD2 as well as treatment with a SMYD2 inhibitor in two NSCLC cell lines with an EML4-ALK gene significantly attenuated the phosphorylation levels of the EML4-ALK protein. Substitutions of each of these three lysine residues to an alanine partially or almost completely diminished in vitro methylation of ALK. In addition, we found that exogenous introduction of EML4-ALK protein with the substitution of lysine 1610 to an alanine in these two cell lines reduced the phosphorylation levels of AKT, one of the downstream oncogenic molecules in the EML4-ALK pathway, and suppressed the growth of the two cell lines. We further showed that the combination of a SMYD2 inhibitor and an ALK inhibitor additively suppressed the growth of these two NSCLC cells, compared with single-agent treatment. Our results shed light on a novel mechanism that modulates the kinase activity of the ALK fused gene product and imply that SMYD2-mediated ALK methylation might be a promising target for development of a novel class of treatment for tumors with the ALK fused gene. P ost-translational modifications play critical roles in protein functions by affecting protein folding, oligomerization, subcellular localization, and protein stability.
A specific subtype of non-small-cell lung cancer (NSCLC) characterized with an EML4-ALK fusion gene, which drives constitutive oncogenic activation of anaplastic lymphoma kinase (ALK), shows a good clinical response to ALK inhibitors. We have reported multiple examples implying the biological significance of methylation on non-histone proteins including oncogenic kinases in human carcinogenesis. Through the process to search substrates for various methyltransferases using an in vitro methyltransferase assay, we found that a lysine methyltransferase, SET and MYND domain-containing 2 (SMYD2), could methylate lysine residues 1451, 1455, and 1610 in ALK protein. Knockdown of SMYD2 as well as treatment with a SMYD2 inhibitor in two NSCLC cell lines with an EML4-ALK gene significantly attenuated the phosphorylation levels of the EML4-ALK protein. Substitutions of each of these three lysine residues to an alanine partially or almost completely diminished in vitro methylation of ALK. In addition, we found that exogenous introduction of EML4-ALK protein with the substitution of lysine 1610 to an alanine in these two cell lines reduced the phosphorylation levels of AKT, one of the downstream oncogenic molecules in the EML4-ALK pathway, and suppressed the growth of the two cell lines. We further showed that the combination of a SMYD2 inhibitor and an ALK inhibitor additively suppressed the growth of these two NSCLC cells, compared with single-agent treatment. Our results shed light on a novel mechanism that modulates the kinase activity of the ALK fused gene product and imply that SMYD2-mediated ALK methylation might be a promising target for development of a novel class of treatment for tumors with the ALK fused gene. P ost-translational modifications play critical roles in protein functions by affecting protein folding, oligomerization, subcellular localization, and protein stability. (1, 2) Lysine methylation on histone proteins is considered one of the most fundamental modifications for orchestrating global gene transcription. (3) (4) (5) (6) (7) (8) In addition, methylation on non-histone proteins has been shown to be dynamically regulated by protein lysine methyltransferases, protein arginine methyltransferases (PRMTs), and demethylases in the last decade. We and others have reported that aberrant methylation of oncoproteins and tumor suppressor proteins plays important roles in development/progression processes of a variety of human cancers. (9, 10) Our previous studies indicated that methylation on non-histone proteins affected subcellular localization, stability, and other modifications of several oncogenic proteins; (9) (10) (11) (12) for example, methylation of heat shock protein 70 by SETD1A promotes its nuclear translocation and interaction with Aurora kinase B. (11) We have also shown that demethylation of lysine residues in MYPT1, a retinoblastoma 1 phosphorylation regulator, by lysine-specific histone demethylase 1 destabilizes the MYPT1 protein and promotes cell cycle progression in cancer cells. (12) Other groups showed that methylation of lysine 372 of p53 by SETD7 increases protein stability and enhances p53 activity, (13) whereas monomethylation of lysine 370 by SMYD2 represses p53 function. (14) Furthermore, the activities of several protein kinases were shown to be under the control of lysine methylation; methylation of vascular endothelial growth factor receptor 1 (15) and AKT1 (16) by SMYD3 leads to enhancement of autophosphorylation. SMYD2 negatively regulates activity of the tumor suppressor phosphatase and tensin homolog and leads to aberrant activation of the AKT pathway. (17) Activation of ALK protein, which is caused by chromosomal translocations, (18) (19) (20) gene amplification, (21) (22) (23) or point mutations, (22, 24) plays a critical role in a small subset of NSCLC. An EML4-ALK fusion gene generated by inversion of the short arm of chromosome 2 is observed in approximately 5% of human NSCLCs. (18, 25) The EML4-ALK fusion oncoprotein requires an N-terminal coiled-coil domain of EML4 which is essential for dimerization of the fusion protein and constitutive activation of ALK kinase. (26) Tyrosine kinase inhibitors binding to an ATP-binding pocket of ALK, such as crizotinib, (27) ceritinib, (28) (29) (30) (31) and alectinib, (32, 33) have been proven their clinical effectiveness for NSCLC with genetic alterations causing aberrant ALK activation. It was also reported that SUMOylation and glycosylation on the NPM-ALK rearranged oncoprotein affected the stability and phosphorylation of the fused protein in neuroblastoma. (34, 35) However, there has been no report indicating post-translational EML4-ALK methylation that may affect the oncogenic activity of this fusion protein.
In the present study, through screening with the in vitro methyltransferase assay and LC-MS/MS analysis, we identified that lysine residues 1451, 1455, and 1610 in an ALK tyrosine kinase domain were likely to be methylated by SMYD2. We further showed that exogenous introduction of EML4-ALK protein with K1610A substitution into two NSCLC cell lines with endogenous EML4-ALK protein dominant-negatively suppressed the growth of these two cell lines. Our results imply the significant role of SMYD2-mediated EML4-ALK methylation in lung carcinogenesis.
Materials and Methods
Cell lines. Human NSCLC cell lines, H3122 and H2228, which have variant 1 and variant 3 of an EML4-ALK fused gene, respectively, and the human embryonic kidney fibroblast cell line 293T were purchased from ATCC (Manassas, VA, USA) and were tested for authentication by DNA profiling with polymorphic short tandem repeat markers (Table S1 ). Four NSCLC cell lines without the EML4-ALK fused gene were purchased from ATCC (for NCI-H1373, NCI-H23, and NCI-H522) or Japanese Collection of Research Bioresources Cell Bank (Suita, Japan) (for VMRC-LCD). 293T cells were cultured in DMEM and the six NSCLC cell lines were grown in monolayers in RPMI-1640 medium supplemented with 10% FBS and 1% antibiotic/antimycotic solution (Sigma-Aldrich, St. Louis, MO, USA). The cells were maintained at 37°C in humid air with 5% CO 2 .
Mass spectrometry analysis. The ALK samples reacted with BSA or SMYD2 in vitro were separated by SDS-PAGE and stained with Simply Blue Safe Stain (Thermo Fisher Scientific, Waltham, MA, USA). The ALK bands were excised and digested in gel with trypsin L-(tosylamide-2-phenyl) ethyl chloromethyl ketone (TPCK-treated; Worthington Biochem, Lakewood, NJ, USA) or endoproteinase Asp-N (Roche Applied Science, Branford, CT, USA). Then the digest peptides were analyzed by nano LC-MS/MS using a Q Exactive mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). The peptides were separated using nano ESI spray column (75 lm [ID] 9 100 mm [L], NTCC analytical column C18, 3 lm; Nikkyo Technos, Tokyo, Japan) with a linear gradient of 0-35% buffer B (100% acetonitrile and 0.1% formic acid) at a flow rate of 300 nL/min over 10 min (Easy nLC; Thermo Fisher Scientific). The mass spectrometer was operated in the positive ion mode, and the MS and MS/MS spectra were acquired in a data-dependent TOP10 method. The MS/ MS spectra were searched against the in-house database using local MASCOT server (version 2.5; Matrix Sciences, Boston, MA, USA). For the quantitative analysis in vivo methylation, ALK peptides were monitored using targeted MS/MS method.
Plasmid construction of substituted proteins. The pcDNA3-EML4-ALK variant 1 with N-FLAG was kindly provided from Professor Hiroyuki Mano at The University of Tokyo (Tokyo, Japan). Using the pcDNA-N-FLAG-tagged EML4-ALK, we constructed lysine-to-alanine substituted plasmid clones using primers purchased from Sigma-Aldrich (sequence is shown in Table S2 ) and KOD Xtreme Hot Start DNA Polymerase (Novagen, Madison, WI, USA) according to manufacturer's protocols.
In vitro methyltransferase assay. A C-terminal portion of ALK (a.a. 1058-1620) including a TKD was subcloned and ligated with pCAGGSn-C-3FLAG. The 293T cells were transfected with WT ALK-TKD expression vector (pCAGGSn-3FLAG-ALK-TKD) or substituted types of ALK-TKD expression vector (pCAGGSn-3FLAG-ALK-TKD K1451A, K1455A, or K1610A). After 48 h of the culture, the protein was immunoprecipitated with anti-FLAG antibody and purified with Amicon Ultra Centrifugal Filters (Millipore, Billerica, MA, USA). For the in vitro methyltransferase assay, recombinant ALK-TKD-WT, ALK-TKD-K1451A, ALK-TKD-K1455A, or ALK-TKD-K1610A was separately incubated with SMYD2 enzyme using 2 lCi S-adenosyl-L-[methyl-
3 H]-methionine (PerkinElmer, Waltham, MA, USA) as the methyl donor in a mixture of 10 lL methylase activity buffer (50 mM Tris-HCl at pH 8.8, 10 mM DTT, and 10 mM MgCl 2 ) for 2 h at 30°C. Proteins were resolved on a Mini PROTEAN TGX Precast gel (Any kD; Bio-Rad, Hercules, CA, USA) and visualized by fluorography using EN3HANCE Spray Surface Autoradiography Enhancer (PerkinElmer). Loading proteins were visualized by MemCode Reversible Protein Stain (Thermo Fisher Scientific).
Antibodies. The following primary antibodies were used; anti-FLAG antibody (mouse, M2; Sigma-Aldrich; dilution used in WB, 1:1000), anti-HA antibody (rat, #11867423001; Roche Applied Science; dilution used in immunocytochemistry (ICC): 1:1000), anti-SMYD2 antibody (rabbit, D14H7; Cell Signaling Technology; dilution used in WB, 1:1000), anti-ALK antibody (rabbit, D5F3; Cell Signaling Technology, Danvers, MA, USA; dilution used in WB, 1:1000), anti-phospho-Y1604-ALK antibody (rabbit; Cell Signaling Technology; dilution used in WB: 1:1000), anti-phospho-Y1278/1282/1283-ALK antibody (rabbit; Cell Signaling Technology; dilution used in WB, 1:1000), anti-phospho-S473-AKT antibody (rabbit; Cell Signaling Technology; dilution used in WB, 1:500), and anti-b-actin antibody (mouse, 8H10D10; Cell Signaling Technology; dilution used in WB, 1:1000).
Western blot analysis. Samples were prepared from the cells lysed with CelLytic M mammalian cell lysis/extraction reagent (Sigma-Aldrich) containing a complete protease inhibitor cocktail (Roche Applied Science) and a phosphatase inhibitor cocktail (Roche Applied Science), and whole cell lysates or immunoprecipitation (IP) products were transferred to 0.45 lm PVDF membrane after electrophoresis. Protein bands were detected by incubating with HRP-conjugated antibodies (GE Healthcare, Chicago, IL, USA) and visualizing with Enhanced Chemiluminescence (GE Healthcare).
Immunoprecipitation. SMYD2 was knocked down in H3122 cells using specific siRNAs. After 96 h of incubation, the cells were lysed with CelLytic M mammalian cell lysis/extraction reagent containing a complete protease inhibitor and a phosphatase cocktail. Whole cell extract was incubated with anti-ALK antibody overnight. The next day, we added 30 lL/well of Protein A Sepharose beads (Invitrogen, Carlsbad, CA, USA) to the cell extract and incubated at 4°C for 1 h. After the beads were washed three times in 1 mL PBS buffer, we added 30 lL/well of Lane Marker Reducing Sample Buffer and denatured the samples, followed by Western blot analysis.
Small interfering RNA transfection. Small interfering RNA oligonucleotide duplexes were purchased from Sigma-Aldrich for targeting the human SMYD2 transcript. siRNA negative control (siNC) was used as a control siRNA. The siRNA sequences are described in Table S3 . Small interfering RNA duplexes (final concentration, 100 nM) were transfected into H3122 and H2228 cells with Lipofectamine RNAiMax Reagent (Thermo Fisher Scientific).
In vitro growth inhibition. LLY-507, a SMYD2-specific inhibitor, was purchased from Sigma-Aldrich. Crizotinib was purchased from (Cayman, Ann Arbor, MI, USA). H2228 and H3122 cells were treated with either or both LLY-507 and crizotinib at the IC 50 concentration; we calculated that the IC 50 values of LLY-507 for H2228 and H3122 cells were 2 and 3 lM, respectively, and the IC 50 values of crizotinib for H2228 and H3122 cells were 0.6 and 0.15 lM, respectively. Protein was harvested after 6 h to examine an early change of the EML4-ALK pathway. After incubation with the inhibitor (s) for 48 h, cells were treated with CCK8, Dojindo (Kumamoto, Japan) (10 lL/100 lL) medium for 3 h in the incubator, and then measured the absorbance at 450 nm using a microplate reader. Growth inhibition rates by the inhibitor(s) on cancer cells were calculated by comparison with control cells. Experiments were done in triplicate.
Statistical analysis. Statistical analyses were carried out using Student's t-test and results are shown as the mean AE SD of three independent experiments. We considered statistically significant when P-values were <0.05.
Results
SMYD2 methylates lysine residues in the C-terminal TKD of ALK. To explore whether ALK serves as a potential substrate of any protein lysine methyltransferases or PRMTs, we undertook the in vitro methyltransferase assay with our recombinant methyltransferase panel (SMYD2, SMYD3, PRMT1, PRMT5, SUV39H2, WHSC1, WHSC1L1, and EZH2) and a recombinant protein corresponding to a TKD of ALK using S-adenosyl-L-[methyl-3 H]-methionine as a methyl resource. As shown in Figure 1 (a), SMYD2 methylated ALK-TKD in a dose-dependent manner, confirming the in vitro methylation of ALK by SMYD2. Then, to identify a candidate methylated site(s), we subjected recombinant ALK-TKD for LC-MS/MS after in vitro methylation of ALK-TKD with SMYD2 and found an increase in the molecular weight of lysine residues at codons 1451, 1455, and 1610 (these numbers are based on the positions in WT full-length ALK protein) (Fig. 1b-d) .
To further confirm SMYD2-mediated methylation at these three residues, we generated four plasmid clones designed to express FLAG-tagged ALK-TKD proteins, WT ALK, and a lysine-to-alanine substituted ALK-TKD at K1451 (K1451A), K1455 (K1455A), or K1610 (K1610A). After immunoprecipitation of these FLAG-tagged proteins, we carried out in vitro methyltransferase assay and found that all three ALK-TKD proteins with the substitution of a lysine residue showed partial or strong impairment of methylation of the ALK-TKD protein (Fig. 1e) . Although we were unable to conclude that the decrease of methylation levels is caused by the direct effect on the methylation site(s) or the indirect effect by the structural changes of the protein by substitution of the lysine residue, the substitution of K1455 and K1610 seemed to affect more significant ALK-TKD methylation by SMYD2. SMYD2 regulates phosphorylation of EML4-ALK. Phosphorylation of certain amino acid residues in ALK is known to be critically important in its oncogenic activity. Hence, we examined the effect of SMYD2-mediated methylation of ALK on the phosphorylation status of EML4-ALK fused protein using two NSCLC cell lines, NCI-H2228 and NCI-H3122, both of which express EML4-ALK fused protein and also express high levels of SMYD2 protein endogenously. We knocked down SMYD2 expression in H2228 and H3122 cells using two siRNAs for SMYD2 (see sequence in Table S3 ), and examined EML4-ALK phosphorylation status by Western blot analysis. As shown in Figure 2(a,b) , knockdown of SMYD2 in H3122 and H2228 cells caused moderate (H3122) and drastic (H2228) decrease of phosphorylation levels at tyrosine 1278/1282/1283 as well as tyrosine 1604 of EML4-ALK. To further validate the effect of SMYD2-mediated methylation on the phosphorylation status of EML4-ALK, we treated these two cell lines with a SMYD2-specific inhibitor, LLY-507, and compared the phosphorylation status of EML4-ALK with the cells treated with an ALK inhibitor, crizotinib, or control. The results showed that the SMYD2 inhibitor LLY-507 reduced phosphorylation levels of tyrosine 1278/1282/1283 and tyrosine 1604 of EML4-ALK to levels similar to those produced by the ALK inhibitor crizotinib (Fig. 2c,d ), implicating the significance of SMYD2-mediated EML4-ALK methylation on phosphorylation levels of tyrosine residues in EML4-ALK that were known to be important for EML4-ALK activity.
Growth of NSCLC cells negatively affected by EML4-ALK pro-
teins with lysine 1610 substitution. To further clarify the significance of SMYD2-mediated methylation on EML4-ALK protein on the growth of cancer cells, we examined the effect of exogenous introduction of lysine-substituted EML4-ALK proteins into two NSCLC cells with EML4-ALK. We prepared eight plasmid clones designed to express a WT EML4-ALK protein or seven lysine-substituted EML4-ALK proteins. Three clones contained a single substitution of lysine to alanine at codon 1451 (K1451A), 1455 (K1455A), or 1610 (K1610A), three clones contained double substitutions of K1451A/ K1455A, K1451A/K1610A, or K1455A/K1610A, and one clone contained three lysine substitutions of K1451A/K1455A/ K1610A. We transfected these eight plasmid clones separately into H3122 and H2228 cells, and measured the phosphorylation status of AKT, a downstream effector of activated EML4-ALK protein. Transfection of WT EML4-ALK or K1451A-, K1455A-, or K1451A/K1455A-subsituted EML4-ALK showed a slight increase of phosphorylation levels of AKT at serine 473 and some tendency of growth promotion for both cancer cells (not statistically significant). However, interestingly, transfection of four clones with lysine 1610 substitution on EML4-ALK significantly reduced AKT phosphorylation levels (Fig. 3, upper panels) . Concordant with the AKT phosphorylation levels, the viability of the two cell lines transfected with the clones with K1610A substitution was much lower than those transfected with other clones (Fig. 3, lower panels) , indicating the dominant-negative growth-suppressive effect of proteins with K1610A substitution. Methylation at lysine 1610 of EML4-ALK by SMYD2 is likely to be very important for the oncogenic activity of EML4-ALK.
Additive growth suppressive effect of dual ALK and SMYD2 inhibition on NSCLC cells with EML4-ALK mutation. We then tested the effect of SMYD2 inhibition on the growth of H2228 and H3122 NSCLC cell lines. We knocked down SMYD2 expression using two siRNAs for SMYD2 (as shown in Fig. 2 ) and examined the viability of H2228 and H3122 cells, and found that knockdown of SMYD2 significantly suppressed the growth of both NSCLC cells (Fig. 4a,b) . First, we found that IC 50 values of LLY-507 (SMYD2 inhibitor) for H2228 and H3122 cells were 2.0 and 3.0 lM, respectively, which were similar to four other NSCLC cell lines not expressing EML4-ALK fused proteins (IC 50 = 1.7-2.6 lM; Fig. S1 ). These findings indicated that SMYD2 might methylate multiple nonhistone proteins involved in proliferation/survival of NSCLC cells, as we reported previously, and treatment with SMYD2 inhibitor would be beneficial to NSCLC patients regardless of harboring EML4-ALK fused proteins. To further investigate the additive effect of SMYD2 inhibition on an ALK inhibitor, (SMYD2  inhibitor) for 48 h, and the relative cell numbers were calculated using the cell counting kit. The mean AE SD of three independent experiments are shown. P-values were calculated using Student's t-test. **P < 0.01.
we treated H2228 and H3122 cells with one or a combination of crizotinib (ALK inhibitor) and LLY-507 at their IC 50 concentration, and found that the combination of these two compounds additively suppressed the growth of the two cancer cell lines with EML4-ALK fused protein (Fig. 4c,d ).
Discussion
Post-translational modifications of various oncoproteins and tumor suppressors are known to play critical roles in tumorigenesis. Modulation of these modifications has been considered promising for the development of a novel class of anticancer treatment. (36) (37) (38) Recent studies have shown that, in addition to epigenetic controls of gene expression through histone methylation, methylation of non-histone protein also contributes to signaling transduction pathways, similar to other post-translational modifications. We and others have reported the important roles of dysregulation of non-histone protein methylation in carcinogenic processes in various types of human cancer. For example, SMYD3-mediated AKT methylation at lysine 14 plays pivotal roles in activation of the AKT signaling pathway in breast and colon cancers, (16) and PRMT1-mediated methylation at arginine 887 of INCENP promotes mitosis of lung and cervical cancers. (39) In the present study, we have shown that SMYD2-mediated methylation of lysine 1610 on the EML4-ALK fusion protein is likely to be critically important for autophosphorylation of some tyrosine residues and the oncogenic activity of the fused proteins. We identified three possible methylation candidate sites in ALK, K1451, K1455, and K1610, with an in vitro methyltransferase assay. To clarify the biological role of methylation at these residues, we constructed plasmid clones, each of which expressed EML4-ALK protein with a substitution(s) of one, two, or all three lysine residues to an alanine. By exogenous introduction of these seven lysine to alaninesubstituted EML4-ALK proteins into two NSCLC cells expressing endogenous EML4-ALK protein, we found that four EML4-ALK proteins, all of which included K1610A substitution commonly, revealed significant reduction of phosphorylation of serine 473 in AKT, one of the growth-signaling molecules activated by EML4-ALK, and showed the dominant-negative growth-suppressive effect on these two cancer cell lines. Hence, we assume that SMYD2-mediated methylation of K1610, which is also physically close to the important phosphorylation site of tyrosine 1604 on ALK, may play a critical role in the oncogenic activity of EML4-ALK. In addition, we showed that knockdown of SMYD2 abolished the in vivo phosphorylation of tyrosine 1278/1282/1283 as well as tyrosine 1604 in the two NSCLC cell lines that have an oncogenic EML4-ALK fused gene.
Due to the intratumoral heterogeneity and the dynamic tumoral evolution during treatment, the clinical effect of monotherapies is generally limited and often not durable. Hence, combination chemotherapy is now applied as an effective strategy to improve the initial response of the treatment and to prevent relapse/recurrence caused by residual cancer cells that are probably resistant to a single agent. (40) In the present study, although the biological mechanism for correlation between the K1610 methylation and Y1604 phosphorylation needs to be further clarified, our data imply the additive growth suppressive effect of the SMYD2 inhibitor to the ALK inhibitor through the enhanced downregulation of phosphorylation of EML4-ALK fused protein and its downstream effector AKT. We also found that SMYD2 inhibitor (LLY-507) showed similar growth-suppressive effects in four NSCLC cell lines harboring TP53 mutations but not harboring either EML4-ALK fused proteins or genetic defects in the APCb-catenin pathway. These findings suggested that SMYD2 might methylate multiple non-histone proteins and activated several signal pathways involved in the proliferation/survival of NSCLC cells. Considering that several other oncoproteins in human tumors are also considered as SMYD2 substrates, (17, 41, 42) targeting SMYD2 may be a promising approach to provide additive effects to other antitumor therapeutics. (10) In conclusion, we identified EML4-ALK as a novel substrate of the protein lysine methyltransferase SMYD2. This methylation might play a critical role in the phosphorylation of EML4-ALK protein and its oncogenic activity. We also suggest that SMYD2 inhibitor might enhance the growth suppressive effect of ALK inhibitors.
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